European pharmaceuticals have returned to investor focus as a defensive sector, and Bernstein has identified three names it believes offer the most attractive combination of valuation, pipeline potential and re-rating catalysts.
In a recent research note, the brokerage singled out AstraZeneca, GSK and Argenx as the most compelling buys. Bernstein’s model assigns price targets that, from today’s levels, imply upside between 36% and 53%.
AstraZeneca - Top large-cap pick
Bernstein places AstraZeneca at the top of its large-cap list. Analysts see double-digit upside to earnings per share as the market is said to be underestimating the value of the company’s non-oncology pipeline. The firm highlights four phase 3 readouts scheduled for 2026-27, among them the Wainua cardiac rare disease programme. Bernstein estimates Wainua could carry peak sales potential equal to roughly one-third of AstraZeneca’s 2025 revenues.
Using a 10x PE30e multiple, Bernstein describes AstraZeneca as one of the cheapest high-quality research and development engines in global pharma and argues that a 35% premium to European peers would be justified. The stock has already risen 21% over the past year, yet analysts contend there remains material room for a re-rating.
GSK - Second among large caps
GSK is Bernstein’s second-ranked large-cap recommendation. The analysts describe the company’s leadership as the most pro-innovation chief executive in two decades and see as much as 27% upside to consensus EPS. A near-term catalyst they flag is the phase 3 readout of camlipixant for chronic cough.
At 9x PE30e, GSK trades at about a 15% discount to its European peers, a gap Bernstein believes understates the scale of the transformation it is undergoing. The company’s own guidance calls for sales of more than A340 billion by 2031, which sits above the A336 billion consensus estimate. Bernstein expects upcoming R&D milestones over the next 12 to 18 months to narrow that divergence.
Argenx - Highest-conviction idea
Across Bernstein’s entire coverage universe, Argenx is cited as the highest-conviction pick. The Belgian immunology specialist has four major phase 3 readouts slated before the end of 2027, including a program in myositis under its Vyvgart franchise. The firm’s EPS regression analysis finds Argenx screens attractively versus US biotech peers.
A E3915 price target from Bernstein implies a 14x PE30e multiple, about an 8% premium to the referenced peer group. Analysts say that premium is warranted based on the company’s track record. Bernstein also praises Argenx management for proactively investing in pipeline diversification, a step the analysts view as materially reducing the risk of the company becoming overly dependent on a single product and unable to offset future patent expiries.
Bottom line
Bernstein’s selections rest on a mix of underappreciated pipeline value, forthcoming clinical catalysts and valuation mismatches relative to peers. The brokerage’s targets imply substantial upside from current market prices for each named stock, and analysts expect that upcoming readouts and R&D milestones will be the key drivers of any re-rating.